CELH
Celsius Holdings, Inc.
CELH has the edge over UTI overall, supported by stronger fundamentals and stronger valuation.
UTI
Universal Technical Institute, Inc.
UTI's outlook is improving, though it still trails on the overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
UTI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Healthy |
UTI's balance sheet is currently healthy, and its revenue and profitability are stable, but its cash flow is under pressure.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH has the edge over UTI in the historical PE scenario, which offers more potential upside but is not a forecast.
UTI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 20x | $12.41 | -44% |
| Forward | 31x | $22.18 | — |
| Fair | 34x | $20.81 | -6.2% |
| Current | 36x | $22.18 | — |
| Expensive | 82x | $49.93 | +125% |
Historical ranges are pointers, not guarantees.
UTI's PE is in its fair range at 36x. If earnings grow as analysts expect, today's price would be 31x next year's earnings.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for CELH, with profitability improving. However, they disagree widely on these estimates.
UTI Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for UTI, with profitability improving.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH earned $0.90 per share over the past year, about eight times what it earned the year before.
UTI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.71 | +17% |
| Q2 2026 | $0.61 | -47% |
| Q1 2026 | $0.76 | -28% |
| Q4 2025 | $0.96 | -2% |
| Q3 2025 | $1.13 | +51% |
| Q2 2025 | $1.15 | +121% |
| Q1 2025 | $1.05 | +176% |
| Q4 2024 | $0.98 | +250% |
| Q3 2024 | $0.75 | +477% |
UTI has the edge over CELH on earnings, with more consistent year-over-year improvement.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH's revenue has grown year over year for six quarters in a row: $847M last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over UTI on profitability, with a higher operating margin.
UTI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $218.9M | +7.2% |
| Q1 2026 | $221.4M | +6.7% |
| Q4 2025 | $220.8M | +9.6% |
| Q3 2025 | $222.4M | +13% |
| Q2 2025 | $204.3M | +15% |
| Q1 2025 | $207.4M | +13% |
| Q4 2024 | $201.4M | +15% |
| Q3 2024 | $196.4M | +15% |
UTI's revenue has grown year over year for 21 quarters in a row: $219M last quarter, up 7.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 1.5% | -5.4 points |
| Q1 2026 | 0.1% | -8 points |
| Q4 2025 | 7.1% | -6.5 points |
| Q3 2025 | 11% | -2 points |
| Q2 2025 | 6.9% | +2.7 points |
| Q1 2025 | 8.1% | +2 points |
| Q4 2024 | 14% | +5.5 points |
| Q3 2024 | 13% | +7.2 points |
UTI's operating margin was 1.5% last quarter, down 5.4 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH has the edge over UTI on cash generation, producing positive trailing cash flow while its opponent burns cash.
UTI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$17.9M | -362% |
| Q1 2026 | -$26.4M | -$14.7M |
| Q4 2025 | -$19.2M | -198% |
| Q3 2025 | $40.6M | -32% |
| Q2 2025 | $6.8M | +128% |
| Q1 2025 | -$11.7M | -$3.3M |
| Q4 2024 | $19.6M | +181% |
| Q3 2024 | $60M | +30% |
UTI's free cash flow was −$23M over the past year, against $75M the year before.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has the edge over UTI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
UTI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +205K shares |
| 1 year | +0.5% | +300K shares |
| 3 years | +64% | +21.9M shares |
| 5 years | +69% | +22.9M shares |
| Available history | +120% | +30.5M shares |
UTI has 56M diluted shares, up 0.5% from a year ago.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over UTI on leverage, with a lower net debt burden relative to earnings.
UTI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.4x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | -0.4x | Net Cash |
| Q2 2025 | 0.0x | Very low |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | -0.5x | Net Cash |
| Q3 2024 | -0.4x | Net Cash |
UTI's net debt is less than a year of its operating earnings (EBITDA).
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
UTI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.3 | Neutral |
| Stochastic | 21.4 | Neutral |
UTI's weekly RSI is 41 (neutral) and its Stochastic is 21 (neutral).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH has the edge over UTI on valuation relative to its sector.
UTI PE vs Consumer Defensive Sector
| Metric | UTI | Sector median | Relative |
|---|---|---|---|
| PE | 36x | 19x | 87% above |
| PE % | 53 | 18 | 35 pts above |
UTI is trading at 36x earnings, a 87% premium to the Consumer Defensive sector's median of 19x.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 29% below its 200-week average.
UTI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.9 | 5.9% above |
| 20 week MA | $27.2 | 18% below |
| 50 week MA | $31.0 | 28% below |
| 100 week MA | $30.0 | 26% below |
| 200 week MA | $21.2 | 4.7% above |
UTI's trend is mixed: it's above two of its five weekly moving averages, and 4.7% above its 200-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH's yearly returns have swung widely, from +832% in 2020 to −51% in 2024. It's down 30% so far in 2026.
UTI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.25 | $6.38 | -12% |
| 2021 | $6.38 | $7.72 | +21% |
| 2022 | $7.72 | $6.15 | -20% |
| 2023 | $6.15 | $12.5 | +104% |
| 2024 | $12.5 | $26.0 | +107% |
| 2025 | $26.0 | $27.3 | +5.2% |
| 2026 YTD | $27.3 | $22.2 | -19% |
UTI has the edge over CELH on returns for 2026, with the stronger performance.